HK Stock Market Move | BIOCYTOGEN-B(02135) rose more than 7% in the afternoon and reached a licensing deal with Tubulis again. The company had reached a collaboration with Merck at the beginning of the month.

BIOCYTOGEN-B(02135) rose more than 7% in the afternoon, as of the time of publication, it has risen 4.07% to 26.58 Hong Kong dollars, with a turnover of 1673.54 million Hong Kong dollars. On the news front, on September 16, BioCytogen announced that it had signed an antibody licensing agreement with the German ADC development company Tubulis, using BioCytogen's self-developed RenMice fully human antibody development platform. Tubulis will combine its proprietary linker and payload technologies to develop innovative ADC therapies. According to the agreement terms, BioCytogen will receive an upfront payment and have the right to receive development, regulatory, and commercialization milestone payments, as well as a single-digit percentage of net sales. It is worth noting that on September 4, BioCytogen had just signed an antibody option and evaluation agreement with the German company Merck, who wanted to evaluate the fully human antibodies developed on BioCytogen's RenMice platform, and jointly develop cutting-edge solutions such as antibody-conjugated lipid nanoparticles (LNP) for nucleic acid drug delivery. Shen Yuelei, Chairman and CEO of BioCytogen, stated that the exercise of the selection rights by Tubulis, as well as the agreement with Merck, both demonstrate the international competitiveness and drug translation potential of the fully human antibody platform.